BOC Sciences, as a global leader in antibody-drug conjugate (ADC) technology services, leverages its profound expertise in biochemistry and advanced technical capabilities to introduce a novel ADC development platform, dedicated to supporting the development and optimization of next-generation ADCs. Our platform offers comprehensive services spanning the entire process, from concept design and molecular engineering to process development and analytical characterization, assisting pharmaceutical and biotechnology companies in overcoming the limitations of traditional ADCs and accelerating the research, development, and commercialization of next-generation ADC candidates.
In addition to providing conventional ADC development, BOC Sciences provides one-stop support services for novel ADC therapies. We remain committed to providing high-quality, customized support for the development of novel ADC therapies and are committed to helping customers advance their innovative drug candidates from concept to clinic.
BOC Sciences' development services for nanobody-drug conjugates (NDCs) fully leverage the unique advantages of nanobodies (VHH), including their small size, high stability, and low immunogenicity. We efficiently conjugate nanobodies with various payloads to enhance tumor tissue penetration and intracellular delivery. By employing advanced conjugation technologies and optimized linker strategies, we ensure NDCs exhibit favorable pharmacokinetic properties and a high therapeutic index.
To address tumor heterogeneity and drug resistance, BOC Sciences offers development services for bispecific antibody-drug conjugates (BsADCs). We design and engineer bispecific antibodies capable of binding two distinct antigens and load potent cytotoxins through precise conjugation techniques. This enables simultaneous targeting of two antigens, enhancing tumor cell killing and the bystander effect. Our team possesses extensive experience in bispecific molecule construction, optimizing structures to balance stability and functionality.
BOC Sciences holds cutting-edge expertise in degrader-antibody conjugates (DACs), especially in the development and application of PROTACs and molecular glue small-molecule degraders. We support the precise conjugation of these novel degraders to antibodies or antibody fragments, enabling targeted degradation of "undruggable" proteins for selective protein knockdown. We address challenges of degrader chemical stability and antibody compatibility by optimizing linker design and conjugation strategies to ensure DACs maintain strong in vivo stability and targeting capability.
In developing antibody fragment-drug conjugates (FDCs), BOC Sciences provides comprehensive solutions from antibody fragment design to efficient conjugation. We specialize in using small antibody fragments such as Fab, scFv, and VHH to improve drug molecule penetration and targeting within the tumor microenvironment. Utilizing advanced conjugation techniques like bioorthogonal chemistry and enzymatic conjugation, we achieve efficient and uniform payload loading, overcoming the limitations of full-length antibodies' large molecular weight and poor tissue penetration.
To tackle complex tumor environments and multiple resistance mechanisms, BOC Sciences supports dual-payload ADC technology. We conjugate two different cytotoxins with distinct mechanisms onto the same antibody, leveraging synergistic effects to enhance antitumor efficacy while reducing resistance risk. Using advanced site-specific conjugation strategies, we ensure even payload distribution and controlled drug-to-antibody ratio (DAR), while optimizing linker structures to enable synchronized or on-demand payload release.
In the area of scaffold-drug conjugates (SDCs), BOC Sciences offers full-service solutions from scaffold protein design to drug conjugation. We support various innovative scaffold proteins, such as Affibody and DARPins, as carriers to overcome the limitations of traditional antibodies' large size and poor tissue penetration. Through precise chemical or enzymatic conjugation technologies, we efficiently load payloads like cytotoxins and immune modulators onto scaffold proteins, maintaining molecular conformational stability and biological activity.
BOC Sciences' ADC development platform covers a broad range of capabilities, including antibody engineering, linker chemistry, payload synthesis, conjugation chemistry, and in vitro and in vivo characterization. The platform leverages state-of-the-art technology and expertise in ADC development to efficiently and cost-effectively generate ADC drug candidates with optimized properties.
BOC Sciences provides a variety of antibody engineering services, including antibody screening, antibody modification and site-specific conjugation. Our team of experienced scientists can help customers identify and optimize monoclonal antibodies, bispecific antibodies and antibody fragments with high specificity and affinity for their target antigens, ensuring successful targeting of cancer cells.
BOC Sciences' ADC development platform includes expertise in linker chemistry, allowing the design and synthesis of a variety of cleavable linkers and non-cleavable linkers. Our linker development capabilities are extensive and technically sophisticated, including chemically labile linkers and enzymatically cleavable linkers. In addition, our platform offers customizable linker options to achieve the required stability, release kinetics, and pharmacokinetic properties of the ADC.
Our ADC platform also provides rapid access to a variety of cytotoxic payloads, as well as custom synthesis services for the development of novel payloads. BOC Sciences' expertise in organic and medicinal chemistry enables the efficient synthesis of potent and selective small molecule drugs for conjugation to antibodies.
Our platform provides expertise in conjugation chemistry, including optimization of conjugation conditions and characterization of ADC conjugates. The platform can be adapted to various conjugation strategies, such as thiol-based, amine-based and click chemistry, to ensure efficient and site-specific conjugation of payloads to antibodies.
In addition, our ADC platform provides ADC characterization and analysis services, including comprehensive in vitro and in vivo analysis services to evaluate the stability, pharmacokinetics and efficacy of ADC drug candidates. BOC Sciences scientists can perform a range of assays, including cell binding, internalization, cytotoxicity and xenograft studies, to evaluate the therapeutic potential of ADCs.
BOC Sciences offers comprehensive support from laboratory-scale experiments to pilot-scale development and GMP process transfer, ensuring the smooth transition of unconventional ADCs from development to large-scale production. Through systematic process optimization, we enhance the repeatability and stability of production processes, ensuring that products meet international standards for quality, consistency, and manufacturability.
BOC Sciences can provide customers with flexible and customizable solutions to meet their specific needs. Our platform can support customers at every stage of the ADC development process, from target identification and antibody selection to preclinical and clinical development. Our ADC one-stop service platform can provide customers with a full range of ADC development support, including:
| Service Item | Service Description |
| ADC Early Discovery | Full-phase support from target validation to lead candidate generation, expediting transition to preclinical development. |
| ADC Formulation Development | Developing and optimizing ADC formulations to improve stability, solubility, and bioavailability for various delivery routes. |
| ADC Process Development | Designing and optimizing scalable manufacturing processes to ensure reproducibility, high yield, and compliance with quality standards. |
| ADC Preclinical Studies | Providing pharmacokinetics, pharmacodynamics, and toxicology studies to support IND submission and clinical trial initiation. |
BOC Sciences provides one-stop services—from antibody engineering and payload synthesis to linker screening, conjugation development, and GMP production—streamlining workflows to save clients time and reduce costs.
BOC Sciences possesses a comprehensive technical platform supporting various types of unconventional ADCs, including antibody fragment conjugates, bispecific ADCs, and degrader ADCs, meeting different therapeutic target and mechanism requirements to help clients create differentiated products.
We offer tailor-made ADC design and process development services based on specific client needs, from molecular design to production processes. We flexibly adjust strategies to enhance project success rates and market competitiveness.
We focus on cutting-edge technologies such as bioorthogonal chemistry, enzymatic conjugation, and precise payload control, supporting the development of unconventional ADCs like fragment-drug conjugates and bispecific ADCs, improving product stability and therapeutic efficacy.
Our experienced project management team follows up throughout the process, flexibly allocating resources, maintaining efficient communication, and responding quickly to client needs. We ensure each development phase is completed on time with high quality, minimizing risks and accelerating clinical progress.
We have established a comprehensive quality management system that spans the entire process from R&D to production, employing advanced analytical techniques to monitor the quality and consistency of each batch of products. This ensures ADC safety and efficacy while meeting global regulatory requirements.
With advanced GMP production facilities, we support everything from small-scale trials to kilogram-level production, complying with ICH and FDA standards. This ensures ADC product purity, consistency, and safety, meeting clinical and commercial needs.
Thanks to efficient project management and extensive experience, BOC Sciences can quickly respond to client needs, shorten project timelines, and adjust R&D plans flexibly, helping clients seize market opportunities.
In the project initiation phase, we work closely with clients to comprehensively assess project requirements, define goals, and develop a development plan. By analyzing target characteristics and market needs, we provide customized conjugation strategies and payload selection recommendations to ensure each project is efficient and has clinical potential. Our goal is to ensure that ADC designs achieve the best balance between efficacy and safety.
We construct and express antibody fragments or bispecific antibodies to ensure precise recognition and binding to target antigens. At the same time, we synthesize and optimize payloads to ensure their biological activity and stability. Based on each project's needs, we also optimize conjugation processes to ensure payload uniformity and conjugation efficiency, maximizing the therapeutic effect of the ADC.
After initial development, we conduct comprehensive physicochemical and biological activity analyses of ADC products, including molecular weight, purity, stability, and DAR as key quality indicators. We ensure that the product's uniformity, stability, and DAR meet international standards, using multiple technologies to guarantee high quality and consistency during clinical phases.
After completing laboratory-scale trials, we conduct pharmacodynamics and toxicology evaluations in animal models to ensure the in vivo efficacy and safety of the ADC. At the same time, the process is scaled up from laboratory to GMP production scale, ensuring consistency and feasibility in production, laying a reliable foundation for subsequent clinical research and commercial production.
We provide cGMP-compliant production services, ensuring ADC product quality consistency from small-scale trials to commercialization. Our production facilities meet global standards and support both preclinical and commercial production needs. Additionally, we assist clients in preparing and filing IND/BLA documentation, helping clients smoothly advance product development.
We provide comprehensive technology transfer support to ensure a smooth transition of laboratory-scale production processes to GMP production stages. We also help clients optimize production workflows, ensuring stable product supply during commercialization, and provide continuous process improvement services to ensure long-term production consistency and quality control.
We follow a strict quality control process at every stage of ADC development, from molecular design to conjugation processes and GMP production, ensuring that each step complies with international standards. Through comprehensive physicochemical properties, stability analysis, and bioactivity testing, we guarantee batch-to-batch consistency in quality. Additionally, all production and testing are conducted in compliance with GMP standards to ensure the high purity and consistency of the products.
In the preclinical phase, we conduct comprehensive pharmacodynamics and toxicology evaluations, including animal model studies, to ensure that the ADC demonstrates strong therapeutic effects and no significant toxicity. Furthermore, after process scaling, we perform stability and purity analyses to ensure that the product meets the required standards before clinical trials.
Yes, BOC Sciences offers GMP-compliant production services. Our GMP production facilities meet the requirements of global regulatory agencies, including FDA and EMA certifications. We are capable of supporting production from small-scale clinical trials to commercial-scale manufacturing, ensuring high quality and consistency for each batch.
Yes, we provide complete technology transfer support services for our clients. Whether it's scaling up from laboratory scale to GMP production or transitioning from R&D to commercial production, we ensure the smooth transfer of production processes and provide technical guidance throughout the process, ensuring product consistency and quality.
